LLAI vs. GENI, IDHC, DMTR, LLA, DXRX, AGL, YGEN, ABDX, PRM, and GDR
Should you be buying LungLife AI stock or one of its competitors? The main competitors of LungLife AI include GENinCode (GENI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), LLA.L,0P0001T9GN,0 (LLA), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), and genedrive (GDR). These companies are all part of the "diagnostics & research" industry.
LungLife AI vs.
GENinCode (LON:GENI) and LungLife AI (LON:LLAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
GENinCode has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, LungLife AI has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500.
In the previous week, GENinCode's average media sentiment score of 0.00 equaled LungLife AI'saverage media sentiment score.
47.6% of GENinCode shares are held by institutional investors. Comparatively, 42.5% of LungLife AI shares are held by institutional investors. 39.8% of GENinCode shares are held by company insiders. Comparatively, 48.4% of LungLife AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
GENinCode and LungLife AI both received 0 outperform votes by MarketBeat users.
LungLife AI has lower revenue, but higher earnings than GENinCode. LungLife AI is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.
LungLife AI has a net margin of 0.00% compared to GENinCode's net margin of -228.70%. LungLife AI's return on equity of -48.59% beat GENinCode's return on equity.
Summary
LungLife AI beats GENinCode on 6 of the 11 factors compared between the two stocks.
Get LungLife AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LungLife AI Competitors List
Related Companies and Tools
This page (LON:LLAI) was last updated on 1/22/2025 by MarketBeat.com Staff
